Abstract Glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide 1 (GLP1) exhibit incretin activity, meaning that they potentiate glucose-dependent insulin secretion
Retatrutide may reduce appetite, but nutritious meals and consistent exercise maintain weight loss for the long haul
Long-term safety data remain under evaluation in ongoing clinical studies
For example, if a beneficiary initiated GLP-1 therapy in September 2024 with a body mass index (BMI) of 37 and has a BMI of 34 at the time of a July 2026 prior authorization request, the prescribing provider should attest that the beneficiary met the BMI 35 criterion at the time therapy was initiated
$3,588 paid up front with no insurance Key Specs Accepts insurance: Yes Weight loss program included: Yes GLP-1 brand names offered: Ozempic, Zepbound, Mounjaro, Wegovy, Trulicity, Rybelsus, Saxenda, Victoza Type of GLP-1 available: Injectable and oral Cancel any time: No Found offers users a care team led by a physician specializing in weight loss
If you have used semaglutide or tirzepatide before, this effect will feel familiar, though the intensity profile differs because retatrutide has relatively lower GLP-1 potency compared to dedicated GLP-1 agonists
